Hologic, Inc. $HOLX Shares Acquired by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in Hologic, Inc. (NASDAQ:HOLX) by 28.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,767,813 shares of the medical equipment provider’s stock after buying an additional 606,782 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Hologic were worth $180,351,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of Hologic by 1.7% during the second quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after buying an additional 97,142 shares during the period. Invesco Ltd. lifted its position in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock worth $298,655,000 after buying an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Hologic by 1.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after purchasing an additional 69,878 shares during the last quarter. Black Creek Investment Management Inc. lifted its stake in Hologic by 26.1% in the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after buying an additional 832,444 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Hologic by 0.8% in the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider’s stock valued at $216,973,000 after purchasing an additional 29,133 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is owned by company insiders.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $74.82 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The business’s 50-day simple moving average is $71.77 and its 200-day simple moving average is $67.37. The firm has a market cap of $16.68 billion, a price-to-earnings ratio of 31.05, a P/E/G ratio of 2.54 and a beta of 0.65. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $80.31.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.01 earnings per share. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on HOLX. Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, Morgan Stanley upped their target price on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Five investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to MarketBeat, Hologic currently has a consensus rating of “Hold” and a consensus target price of $79.67.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.